Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
$15.00
$14.97
$3.06
$15.00
$521.45M1601,442 shs247,800 shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$21.35
+9.3%
$18.98
$14.40
$47.00
$1.42B1.33918,647 shs852,592 shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$6.16
+3.4%
$6.61
$5.81
$12.65
$1.90B0.542.94 million shs5.15 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$105.99
+1.7%
$104.32
$77.43
$129.90
$2.04B0.83115,851 shs91,810 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
0.00%+9.54%+9.38%+3.29%-35.32%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%+0.82%+1.32%-30.47%-41.22%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.00%+2.73%+3.39%-7.70%+26.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
1.9778 of 5 stars
4.50.00.00.03.50.00.0
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
3.8917 of 5 stars
3.41.00.04.32.40.01.9
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.8122 of 5 stars
3.53.00.04.43.53.31.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.00
N/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.90
Moderate Buy$53.90152.46% Upside
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.70
Moderate Buy$16.22163.35% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$146.1437.88% Upside

Current Analyst Ratings Breakdown

Latest AVEO, LGND, FOLD, and CLDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $38.00
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.00
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.00
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
5/6/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/2/2025
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $22.00
5/2/2025
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.00
4/28/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$64.00
4/10/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$143.00
3/20/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$46.00
(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
$42.29M12.33N/AN/A$1.33 per share11.28
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$7.56M187.50N/AN/A$9.08 per share2.35
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$543.14M3.49N/AN/A$0.63 per share9.78
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$181.49M11.27$4.35 per share24.39$40.39 per share2.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%8/6/2025 (Estimated)
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$151.58M-$0.09N/A14.331.51-10.62%12.44%2.60%8/14/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$52.15M-$7.1242.2328.57N/A29.68%4.95%4.39%8/5/2025 (Estimated)

Latest AVEO, LGND, FOLD, and CLDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.94
2.37
2.35
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
24.27
24.27
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.01
3.39
2.42
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
12.49
11.81

Institutional Ownership

CompanyInstitutional Ownership
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
49.95%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
11434.76 million33.62 millionOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15066.38 million63.82 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480307.93 million292.23 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.29 million17.78 millionOptionable

Recent News About These Companies

LGND: 1Q:25 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVEO Pharmaceuticals stock logo

AVEO Pharmaceuticals NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$21.35 +1.82 (+9.32%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$21.68 +0.33 (+1.54%)
As of 06/6/2025 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

$6.16 +0.20 (+3.36%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$6.19 +0.03 (+0.50%)
As of 06/6/2025 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$105.99 +1.81 (+1.74%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$106.08 +0.09 (+0.08%)
As of 06/6/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.